J Korean Ophthalmol Soc.  2012 Sep;53(9):1276-1284. 10.3341/jkos.2012.53.9.1276.

Short-Term Visual Outcomes According to Patterns of Macular Edema in Retinal Vein Occlusion Patients

• Park KH
• Rho IH

• KMID: 2216080
• DOI: http://doi.org/10.3341/jkos.2012.53.9.1276

Abstract

PURPOSE
To study the short-term visual outcomes affected by the patterns of macular edema in retinal vein occlusion patients.
METHODS
In a retrospective study, 33 eyes of 33 consecutive patients with macular edema from retinal vein occlusion received an intravitreal injection of bevacizumab. Macular edema was classified according to OCT patterns and the effect on visual outcome evaluated: Diffuse macular edema (DME) vs. focal macular edema (FME), and macular edema with serous retinal detachment (SRD) vs. macular edema without serous retinal detachment (non-SRD).
RESULTS
Nine patients had CRVO, 24 patients had BRVO and the follow-up period was 3.6 months. In the FME group, the mean baseline BCVA was 0.61 +/- 0.34 and the final BCVA was 0.26 +/- 0.29, a difference that was statistically significant (p < 0.01). In the DME group, the mean baseline BCVA was 0.85 +/- 0.44 and the final BCVA was 0.73 +/- 0.37, a difference that was not statistically significant (p = 0.07). In the non-SRD group, the mean baseline BCVA was 0.76 +/- 0.43 and the final BCVA was 0.38 +/- 0.36, a difference that was statistically significant (p < 0.01). In the SRD group, the mean baseline BCVA was 0.73 +/- 0.40 and the final BCVA was 0.64 +/- 0.42, a difference that was not statistically significant (p = 0.07).
CONCLUSIONS
Visual outcome was significantly better in the FME and non-SRD groups. The patterns of macular edema measured according to OCT were a prognostic factor for visual outcome.

Keyword

Bevacizumab; Macular edema; Optical coherence tomography; Retinal vein occlusion

MeSH Terms

Antibodies, Monoclonal, Humanized
Eye
Follow-Up Studies
Humans
Intravitreal Injections
Macular Edema
Retinal Detachment
Retinal Vein
Retinal Vein Occlusion
Retinaldehyde
Retrospective Studies
Tomography, Optical Coherence
Bevacizumab
Antibodies, Monoclonal, Humanized
Retinaldehyde

Figure

• 

  Figure 1 The classification of macular edema in retinal vein occlusion on spectral-domain optical coherent tomographic images. (A) Diffuse thickening of the whole retinal layer (DME group). (B) Focal thickening of the retina (FME group).

• 

  Figure 2 The classification of macular edema in retinal vein occlusion on spectral-domain optical coherence tomographic images. (A) Macular edema with serous retinal detachment (SRD group). (B) Macular edema without serous retinal detachment (Non-SRD group).

• 

  Figure 3 Changes in visual acuity of DME group and FME group in patients with macular edema associated with retinal vein occlusion. DME = diffuse macular edema; FME = focal macular edema; BCVA = best corrected visual acuity; log MAR = logarithm of the minimal angle of resolution. p < 0.05 by Wilcoxon signed rank test was considered to be significant.

• 

  Figure 4 Changes in visual acuity of SRD group and Non-SRD group in patients with macular edema associated with retinal vein occlusion. SRD = macular edema with serous retinal detachment; Non-SRD = macular edema without serous retinal detachment; BCVA = best corrected visual acuity; log MAR = logarithm of the minimal angle of resolution. p < 0.05 by Wilcoxon signed rank test was considered to be significant.

Reference

1. The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol. 1984. 98:271–282.

2. Hee MR, Puliafito CA, Wong C, et al. Quantitative assessment of macular edema with optical coherence tomography. Arch Ophthalmol. 1995. 113:1019–1029.

3. Konno S, Akiba J, Yoshida A. Retinal thickness measurements with optical coherence tomography and the scanning retinal thickness analyzer. Retina. 2001. 21:57–61.

4. Ghil HK, Cho SW, Kim SH. The efficacy of intravitreal triamcinolone acetonide for macular edema in branched retinal vein occlusion. J Korean Ophthalmol Soc. 2004. 45:2029–2035.

5. Lee H, Shah GK. Intravitreal triamcinolone as primary treatment of cystoid macular edema secondary to branch retinal vein occlusion. Retina. 2005. 25:551–555.

6. Noma H, Funatsu H, Yamasaki M, et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol. 2005. 140:256–261.

7. Priglinger SG, Wolf AH, Kreutzer TC, et al. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Retina. 2007. 27:1004–1012.

8. Jaissle GB, Ziemssen F, Petermeier K, et al. [Bevacizumab for treatment of macular edema secondary to retinal vein occlusion]. Ophthalmologe. 2006. 103:471–475.

9. Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina. 2006. 26:279–284.

10. Yang HN, Kim YJ, Kim JC, Shyn KH. Clinical evaluation for branch retinal vein occlusion. J Korean Ophthalmol Soc. 1992. 33:599–604.

11. Green WR, Chan CC, Hutchins GM, Terry JM. Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases. Trans Am Ophthalmol Soc. 1981. 79:371–422.

12. The Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol. 1997. 115:486–491.

13. Rehak J, Rehak M. Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res. 2008. 33:111–131.

14. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994. 331:1480–1487.

15. Funatsu H, Yamashita H, Nakamura S, et al. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology. 2006. 113:294–301.

16. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging. 2005. 36:336–339.

17. Gündüz K, Bakri SJ. Intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion. Eye (Lond). 2008. 22:1168–1171.

18. Jaissle GB, Leitritz M, Gelisken F, et al. One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2009. 247:27–33.

19. Rabena MD, Pieramici DJ, Castellarin AA, et al. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina. 2007. 27:419–425.

20. Ach T, Hoeh AE, Schaal KB, et al. Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2010. 248:155–159.

21. Kang SJ, Chin HS, Moon YS. Visual prognosis of macular edema associated with macular ischemia in branch retinal vein occlusion. J Korean Ophthalmol Soc. 2002. 43:1621–1628.

22. Wolf-Schnurrbusch UE, Ghanem R, Rothenbuehler SP, et al. Predictors of short-term visual outcome after anti-VEGF therapy of macular edema due to central retinal vein occlusion. Invest Ophthalmol Vis Sci. 2011. 52:3334–3337.

23. Ota M, Tsujikawa A, Murakami T, et al. Foveal photoreceptor layer in eyes with persistent cystoid macular edema associated with branch retinal vein occlusion. Am J Ophthalmol. 2008. 145:273–280.

24. Hoeh AE, Ruppenstein M, Ach T, Dithmar S. OCT patterns of macular edema and response to bevacizumab therapy in retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2010. 248:1567–1572.

25. Schatz H, Yannuzzi L, Stransky TJ. Retinal detachment secondary to branch vein occlusion: Part II. Ann Ophthalmol. 1976. 8:1461–1471.

26. Lee SW, Kim HK, Kim SY. Patterns of macular edema in patients with branch retinal vein occlusion on optical coherence tomography. J Korean Ophthalmol Soc. 2005. 46:969–975.

27. Otani T, Kishi S, Maruyama Y, et al. Patterns of diabetic macular edema with optical coherence tomography. Am J Ophthalmol. 1999. 127:688–693.

28. Kang SW, Park CY, Ham DI. The correlation between fluorescein angiographic and optical coherence tomographic features in clinically significant diabetic macular edema. Am J Ophthalmol. 2004. 137:313–322.

29. Park SP, Ahn JK, Mun GH. Aqueous vascular endothelial growth factor levels are associated with serous macular detachment secondary to branch retinal vein occlusion. Retina. 2010. 30:281–286.

30. Yamaguchi Y, Otani T, Kishi S. Serous macular detachment in branch retinal vein occlusion. Retina. 2006. 26:1029–1033.

31. Yamaike N, Tsujikawa A, Ota M, et al. Three-dimensional imaging of cystoid macular edema in retinal vein occlusion. Ophthalmology. 2008. 115:355–362.